JPRN-jRCTs051230150尚未招募2 期
A Phase II Study of the Preventive Effectiveness and Safety of Lubiprostone in Opioid-Induced Constipation (OIC) Caused by Opioid Analgesics for the Treatment of Cancer Pain
Kuriyama Toshiyuki0 个研究点目标入组 37 人开始时间: 2023年12月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. cancer patients over 18 years of age who are involved with the Palliative Care Team and Palliative Care Unit
- •2. patients not currently receiving opioid analgesics
- •3. patients who are receiving opioid analgesics (morphine, oxycodone, hydromorphone, tapentadol, fentanyl, tramadol, codeine phosphate) for the first time for cancer pain
排除标准
- •1. patients with diagnosed or suspected intestinal obstruction
- •2. patients who are unable to take oral intake
- •3. patients with ECOG PS4
- •4. patients who have difficulty in obtaining written consent and completing the questionnaire
- •5. patients with Child-Pugh B or C
- •6. patients with eGFR less than 30 mL/min/1.73 m2
- •7. Patients with a history of allergy or contraindication to Lubiprostone
- •8. patients with diarrhea (Bristol stool scale 6 or 7)
- •9. patients with a history of irritable bowel syndrome
研究者
相似试验
已完成
2 期
Phase II study of the effectiveness of prophylaxis against side effects associated with Afatinib (NLCTG 1401)non-small cell lung cancerJPRN-UMIN000016167iigata Lung Cancer Treatment Group30
进行中（未招募）
1 期
Study of Efficacy of REVTx-99 against Influenza infection.Influenza AEUCTR2021-003463-97-BERevelation Biosciences, Inc.60
招募中
2 期
High humidity decreases symptomatic patent ductus arteriosusJPRN-jRCT1032190068Hirata Michisato30
招募中
2 期
A phase 2 study, investigating prevention and treatment algorism of the skin toxicity related with Panitumumab treatment in patients with unresectable and/or metastatic CRC with KRAS wild type refractory to 5-FU containing chemotherapyJPRN-UMIN000005862ational Cancer Center Hospital East40
进行中（未招募）
1 期
A study to investigate the protective effects of Glucagonlike Peptide1 (GLP-1) in patients undergoing elective angioplasty and stenting.To determine whether an infusion of GLP1 can reduce the occurrence of myocyte necrosis and infarction caused by percutaneous coronary interventionMedDRA version: 18.0Level: PTClassification code 10066592Term: Post procedural myocardial infarctionSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 18.0Level: LLTClassification code 10002380Term: Angina of effortSystem Organ Class: 100000004849EUCTR2013-001967-22-GBPapworth Hospital NHS Foundation Trust400